Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 1
2013 1
2014 4
2015 16
2016 23
2017 15
2018 18
2019 22
2020 26
2021 17
2022 9
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 32366392

144 results

Results by year

Filters applied: . Clear all
Page 1
A Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft (PDOX) Mouse Model Is Sensitive to Bevacizumab and Vinorelbine, Regressed by Eribulin and Resistant to Olaparib.
Yamamoto J, Murata T, Tashiro Y, Higuchi T, Sugisawa N, Nishino H, Inubushi S, Sun YU, Lim H, Miyake K, Hongo A, Nomura T, Saitoh W, Moriya T, Tanino H, Hozumi C, Bouvet M, Singh SR, Endo I, Hoffman RM. Yamamoto J, et al. Anticancer Res. 2020 May;40(5):2509-2514. doi: 10.21873/anticanres.14221. Anticancer Res. 2020. PMID: 32366395
Eribulin Regresses a Cisplatinum-resistant Rare-type Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft Mouse Model.
Yamamoto J, Murata T, Sugisawa N, Higuchi T, Tashiro Y, Nishino H, Inubushi S, Sun YU, Lim H, Miyake K, Shimoya K, Nomura T, Kurebayashi J, Tanino H, Hozumi C, Bouvet M, Singh SR, Endo I, Hoffman RM. Yamamoto J, et al. Anticancer Res. 2020 May;40(5):2475-2479. doi: 10.21873/anticanres.14217. Anticancer Res. 2020. PMID: 32366391
Eribulin regresses a doxorubicin-resistant Ewing's sarcoma with a FUS-ERG fusion and CDKN2A-deletion in a patient-derived orthotopic xenograft (PDOX) nude mouse model.
Miyake K, Murakami T, Kiyuna T, Igarashi K, Kawaguchi K, Li Y, Singh AS, Dry SM, Eckardt MA, Hiroshima Y, Momiyama M, Matsuyama R, Chishima T, Endo I, Eilber FC, Hoffman RM. Miyake K, et al. J Cell Biochem. 2018 Jan;119(1):967-972. doi: 10.1002/jcb.26263. Epub 2017 Sep 12. J Cell Biochem. 2018. PMID: 28681998
CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer.
Xiang J, Hurchla MA, Fontana F, Su X, Amend SR, Esser AK, Douglas GJ, Mudalagiriyappa C, Luker KE, Pluard T, Ademuyiwa FO, Romagnoli B, Tuffin G, Chevalier E, Luker GD, Bauer M, Zimmermann J, Aft RL, Dembowsky K, Weilbaecher KN. Xiang J, et al. Mol Cancer Ther. 2015 Nov;14(11):2473-85. doi: 10.1158/1535-7163.MCT-15-0252. Epub 2015 Aug 12. Mol Cancer Ther. 2015. PMID: 26269605 Free PMC article.
Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.
Yoshida T, Ozawa Y, Kimura T, Sato Y, Kuznetsov G, Xu S, Uesugi M, Agoulnik S, Taylor N, Funahashi Y, Matsui J. Yoshida T, et al. Br J Cancer. 2014 Mar 18;110(6):1497-505. doi: 10.1038/bjc.2014.80. Epub 2014 Feb 25. Br J Cancer. 2014. PMID: 24569463 Free PMC article.
144 results